Researchers have built a single-cell atlas of alternative polyadenylation in the aged human brain, adding a new layer to the genetics of Alzheimer’s disease and other brain disorders. The study, published in Nature Genetics, spans 2 million cells from 379 postmortem brains and identifies how noncoding variation can shape disease risk through 3′ untranslated region choice rather than gene expression alone.
A new layer of brain genetics
Alternative polyadenylation, or APA, influences the fate of messenger RNA by changing where transcripts end. In the new analysis, APA patterns were mapped at cell type resolution across major brain cell populations, including excitatory and inhibitory neurons, astrocytes, oligodendrocytes, oligodendrocyte progenitor cells, microglia and vascular cells. The researchers report that APA changes in Alzheimer’s disease were often distinct from expression changes, yet still converged on pathways linked to microglial activation and microtubule transport in neurons.
The team integrated APA data with whole-genome sequencing and identified cell-type-resolved 3′ untranslated region quantitative trait loci, or 3′aQTLs, for 4,288 genes. These 3′aQTLs were more likely to colocalize with protein QTLs than with expression QTLs, suggesting that APA can capture biology that standard expression analyses may miss.
Links to Alzheimer’s, Parkinson’s and schizophrenia
Across 17 brain traits and diseases, the study identified 168 GWAS loci dependent on 3′aQTLs, and only 17.5% of those overlapped with eQTLs. Among the highlighted loci were PLEKHA1 and APOC2 for Alzheimer’s disease, PAK6 and AP3B2 for schizophrenia, NDUFA13 for bipolar disorder, MTCH2 for multiple brain traits, and SNCA, the top locus in Parkinson’s disease.
The authors also show that 3′ untranslated region choice can alter SNCA mRNA localization inside the cell, consistent with an eQTL-independent effect in neurons and oligodendrocytes. That finding suggests some disease risk may be driven by post-transcriptional regulation rather than by changes in transcript abundance alone.
Why it matters for precision medicine
The study provides a cell-type-specific map of APA in the human brain and offers a framework for interpreting noncoding genetic risk in neurodegeneration and psychiatric disease. By separating APA effects from expression effects, the work may help researchers prioritize variants and pathways for future functional studies and therapeutic development.
For UK clinicians and researchers, the findings add to a growing body of genomics work showing that disease biology can be missed if analyses focus only on protein-coding change. The study points to a future in which cell-specific regulatory mechanisms, including 3′ UTR usage, become part of routine genetic interpretation in complex brain disorders.
Photo source: AI-generated or edited image
